Abstract More than 75% of breast cancers that develop in BRCA1 mutation carriers are triple-negative breast cancers (TNBC). The aim of this study was to compare the recurrence-free survival (RFS) and overall survival (OS) in high-risk patients with TNBC with and without deleterious BRCA1/2 mutations. A total of 227 women with TNBC who were referred for genetic counseling and underwent BRCA genetic testing between 1997 and 2010 were included in the study. The relationships between clinical variables and outcomes were evaluated using univariate and multivariate Cox proportional hazard regression models. Of 227 high-risk women with TNBC, 50% (n = 114) tested positive for BRCA1/2 mutations. Age, race, and tumor characteristics did not differ between BRCA noncarriers and carriers. At a median follow-up of 3.4 years, the 5-year RFS rates were 74 and 81% (P = 0.21), and 5-year OS rates were 85 and 93% in BRCA non-carriers and BRCA carriers, respectively (P = 0.11). In a multivariate model, after adjusting for age and disease stage, BRCA carriers tended to have a decreased risk of recurrence (HR = 0.67; 95% CI: 0.38-1.19; P = 0.17) or death (HR = 0.51; 95% CI:0.23-1.17; P = 0.11) compared to non-carriers. Our data indicate a 50% prevalence of deleterious BRCA1/2 mutations in high-risk women diagnosed with TNBC. Overall prognosis of TNBC in BRCA carriers and non-carriers is not significantly different within the first 5 years following an initial diagnosis. Further studies need to evaluate whether different therapies will change the outcome in these subgroups of TNBC.
Introduction
Triple-negative breast cancers (TNBC) are defined as tumors that lack expression of estrogen receptor (ER) and progesterone receptor (PR), but express human epidermal growth factor receptor-2 (HER2) at normal levels. TNBC affects 10-17% of all invasive breast cancers and is associated with poor prognosis. Microarray-based expression profiling studies have revealed five intrinsic subgroups of breast cancer, one of which is basal-like breast cancer [1] . This subgroup is characterized by an absence or low levels of expression of ER, an absence of HER2 overexpression, and expression of genes usually found in basal cells of the normal breast [1, 2] . Although the majority of TNBC (approximately 80%) are also basal-like breast cancers, 18-40% of basal-like cancers do not have a triple-negative phenotype on immunohistochemical analysis (IHC) [3] .
Immunohistochemical studies [4, 5] and expression arrays [6] have shown similarities between BRCA1 tumors and basal-like breast carcinomas. More than 75% of tumors arising in women carrying a BRCA1 mutation display a triple-negative phenotype, a basal-like phenotype, or both [2, 7] . Despite the higher prevalence of TNBC among BRCA mutation carriers, it is controversial whether BRCA carriers have lower survival, and previous studies have reported inconsistent results [8, 9] . With the presentation of the results of a recent large population study [10] , it is an accepted general opinion that outcome for BRCA1/2 mutation carriers is at least as good as for non-carriers. Preclinical studies have suggested that lack of functioning BRCA1 or BRCA2 protein may result in differential treatment response to several agents targeting aberrant DNA repair pathways [11, 12] . Therefore, determining the prevalence of BRCA mutations in high-risk women with TNBC and survival outcomes in BRCA mutation-associated and non-BRCA mutation-associated TNBC is critical for the design of future clinical trials with novel therapeutics.
As a result, we conducted this retrospective analysis to determine whether there were any differences in the recurrence-free survival (RFS) and overall survival (OS) of patients with BRCA mutation-associated TNBC and non-BRCA mutation-associated TNBC.
Materials and methods

Patient population and data collection
The prospectively maintained Breast Cancer Management System database at the University of Texas MD Anderson Cancer Center (MDACC) identified 231 women with TNBC who were referred for genetic counseling and underwent genetic testing for mutations in the BRCA1 and BRCA2 genes between 1997 and 2010. All women were physician-referred to the Clinical Cancer Genetics Program at UTMDACC Breast Center based on family history (FH), and they were young aged (B50 years). Patients with bilateral disease, metastatic breast cancer, previous history of breast cancer (BC), or whose BRCA mutations indicated a variant of uncertain significance were excluded from the analysis.
This study was approved by the MDACC Institutional Review Board. The retrospective analysis of prospectively collected data included age at the time of diagnosis, FH of BC and/or ovarian cancer (OC), number of relatives affected with BC and/or OC, patient demographics, tumor characteristics, initial clinical stage, type of chemotherapy received, and surgery, recurrence and survival information.
Pathologic assessment and mutation analysis All pathologic specimens were reviewed by dedicated breast pathologists at MDACC. Invasive carcinoma was confirmed on initial core biopsy specimens. Initial clinical stage and pathologic stage of all patients were revised and based on the sixth edition of the American Joint Committee on Cancer (AJCC) staging criteria [13] . Tumor grade was defined according to the modified Black's nuclear grading system [14] . Negative ER and PR status was defined as nuclear staining of B10% on IHC. HER2-negative status was defined as either B2? or no staining by IHC and/or absence of gene amplification by fluorescence in situ hybridization.
BRCA testing was performed using germline DNA (from blood) by Myriad Genetics Laboratories Inc. (Salt Lake City, UT), and the test results were categorized as either positive or negative for a deleterious mutation.
Treatment
The types of chemotherapy received were at the discretion of the patient and multidisciplinary treating team. Neoadjuvant and adjuvant chemotherapy regimens comprised of anthracycline-taxane-containing regimens (AT) (n = 159); anthracycline-based regimens without a taxane (A) (n = 41); or single-agent taxane (T) (n = 5). Anthracycline-containing regimens included 3-6 cycles of one of the following: FEC100 All patients underwent definitive surgery either before or after genetic testing. Contralateral prophylactic mastectomy (CPM) and bilateral prophylactic oophorectomy (BPO) were performed in women without evidence of metastatic disease. Postoperative radiotherapy was administered if patients had breast conserving surgery (BCS), locally advanced disease at presentation, primary tumor of greater than 5 cm, or equal or greater than four involved axillary nodes. None of the patients received adjuvant endocrine therapy.
Statistical analysis and outcome measures
The demographic and clinical characteristics were summarized and compared between BRCA status group (noncarrier or carrier) by the chi-square test or Fisher's exact test. RFS was calculated from the time of surgery until the first date of documented disease recurrence or death or the date of last follow-up. OS was calculated from the time of surgery until the date of death from any cause or last follow-up. Patients not experiencing the relevant end points were censored at last follow-up. Survival outcomes were estimated using the Kaplan-Meier product-limit method and tested for differences between/among groups by logrank test. Cox proportional hazards models were fitted to determine the association of BRCA status with time to event outcomes after adjustment for significant patient and clinical characteristics identified in univariate analyses. Of note, because of the high correlation between BRCA status and performance of BPO, to avoid colinearity, BPO was not included in the same multicovariate model. P-values B0.05 were considered statistically significant; all tests were two-sided. Statistical analysis was carried out using SAS 9.1.3 (SAS Institute Inc., Cary, NC) and S-Plus 8.0 (Insightful Corporation, Seattle, WA).
Results
Patient demographics and clinical characteristics
A total of 227 patients were identified for this analysis, of whom 50% (n = 114) were BRCA carriers, 82% (n = 94) were found to carry a BRCA1 mutation, and 19% (n = 20) were found to have a BRCA2 mutation. The prevalence of BRCA mutations with regard to patient demographics and clinical characteristics is displayed in Table 1 . Age and menopausal status at diagnosis, race, nuclear grade, and initial clinical stage were not predictive of BRCA mutation status.
Nine patients had a previous history of OC, of whom eight had either BRCA1 (n = 4), or BRCA2 (n = 4) mutations, and one patient had both BRCA1 and two mutations. Among patients who did not report any FH of BC or OC (n = 47), the BRCA1/2 mutation prevalence was 23.4% (n = 11). Patients with a FH of BC or OC had a higher risk of having BRCA mutations compared to patients without any FH of BC or OC (57 vs. 29%; P \ 0.001, and 77 vs. 41%; P \ 0.001, respectively). Similarly, BRCA mutations were more frequently identified in patients with C2 family members with BC or OC compared to those with fewer relatives (P \ 0.001).
Treatment effect
There were no significant differences in the use of chemotherapy regimen and type with respect to BRCA mutation status. Among the study population, the majority of patients (70%) received one of the anthracycline-taxane-containing regimens as neoadjuvant or adjuvant systemic therapy. Of 80 patients who were initially treated with neoadjuvant systemic chemotherapy (NST), 39% (n = 31) had stage III disease.
BCS was performed in 61% (n = 49) of patients in the BRCA non-carrier group vs. 39% (n = 31) in the BRCA carrier group (P = 0.007). Seventy-three percent of women (41/56) underwent BPO after genetic testing, and 59% (n = 33) of these women had a BPO within 1 year of receiving their test results. As expected, BPO was more frequently employed in BRCA carriers (91%) compared with BRCA non-carriers (9%) (P \ 0.001). Likewise, 64% (n = 55) of carriers underwent a CPM while only 36% (n = 31) of non-carriers did (P = 0.001). However, this difference did not remain significant among patients B40 years of age. Among those patients, CPM was performed in 39% (n = 22) of carriers and in 25% (n = 14) of non-carriers (P = 0.09).
Survival estimates
Median follow-up of survivors was 3.4 years (range 0.02-21.0 years). A total of 25 deaths, and 51 recurrences or deaths were observed. The estimated 5-year RFS rates were 74% for BRCA non-carriers versus 81% for BRCA carriers (P = 0.21) (Fig. 1a) . In univariate analyses, clinical stage III status and having received NST were factors associated with increased risk of breast cancer recurrence (Table 2 ). In contrast, older age ([40 years) and undergoing BPO were associated with a lower risk of recurrence. In the multivariate Cox proportional hazards model, patients with stage III disease had a higher risk of recurrence (HR = 3.81; 95% CI:1.58-9.20; P = 0.003), and older patients had a decreased risk of recurrence (HR = 0.39; 95% CI:0.21-0.71; P = 0.002). After adjusting for these significant clinical variables, BRCA status was not associated with RFS (HR = 0.67; 95% CI:0.38-1.19; P = 0.17).
The estimated 5-year OS rates were not significantly different among the two groups (85% in the BRCA noncarriers, and 93% in the BRCA carriers, P = 0.11) (Fig. 1b) . In univariate analyses, clinical stage III status and treatment with NST were associated with increased risk for all-cause death, and older age and undergoing BPO were associated with a lower risk for death (Table 2) . In multivariate analysis, while patients with stage III disease had a worse OS (HR = 3.39; 95% CI:1.03-11.13; P = 0.04), older patients had a better OS (HR = 0.41; 95% CI:0.17-0.95; P = 0.04). After adjusting for age and disease stage, BRCA status was not associated with OS (HR = 0.51; 95% CI:0.23-1.17; P = 0.11) ( Table 3 ).
Discussion
Our data indicate an overall 50% prevalence of deleterious BRCA1/2 mutations in a highly selected population of high-risk women with TNBC. To the best of our knowledge, this is the highest incidence of BRCA mutations reported up to date. We show that BRCA status does not adversely impact survival outcomes in patients with TNBC; in fact, BRCA carriers tend to have a decreased risk of breast cancer recurrence and death. Clinically, the triple-negative or basal-like phenotype indicates the possible presence of a germline BRCA1 mutation. Few studies have assessed the mutation prevalence in women with TNBC who were selected for young age, FH or ethnic group, with reported rates of 24-29% [4, [15] [16] [17] . The BRCA1 mutation rate of 29% was among women with ER-negative, high-grade tumors who were diagnosed before the age of 35 [17] . Of note, only one of the BRCA1 carriers had a significant FH. Other observational studies have looked at the incidence of BRCA1/2 mutations in small selected cohorts of TNBC. Young et al. [18] examined 54 women with high-grade TNBC diagnosed at or before age 40 who had no significant FH; six (11%) of whom were found to carry BRCA mutations (five in BRCA1 and one in BRCA2). Similarly, in another study [19] , the BRCA1 mutations were detected in 11.3% (20/ 177) of women with TNBC, and mutation prevalence was significantly higher than estimated by Myriad prevalence tables in the entire group. Furthermore, recent work from our institution showed a 19.5% BRCA mutation rate in an unselected patient cohort of TNBC, and almost half of the mutation carriers were not referred to genetic counseling or tested mostly due to having insufficient documented risks such as older age, lack of significant FH or insurance difficulties [20] . Kwon et al. [21] showed that interventions based on BRCA mutation testing results of women with TNBC who are younger than 50 years reduced subsequent breast and ovarian cancer risks by 23 and 41%, respectively. After these results, NCCN guidelines changed the criteria for further risk evaluation and now recommend referral for cancer genetic assessment in all individuals diagnosed with TNBC under the age of 60 [22] .
Multiple studies have indicated that triple-negative and basal-like breast cancers, as a group, are associated with an adverse prognosis. During the first 5 years after diagnosis, there is a significantly increased risk for recurrence and death, but distant relapse after this time is much less common [23] [24] [25] [26] . While most studies show a similar prognosis for women with hereditary breast cancers compared to age-matched women with sporadic breast cancers [10, [27] [28] [29] [30] [31] [32] , other studies have reported worse survival outcomes [33] [34] [35] [36] [37] . Notably, Cortesi et al. [38] reported a better prognosis in BRCA1 mutation carriers compared with BRCA mutation non-carriers and patients with sporadic breast cancer; OS estimates were 77% versus 77% versus 73%, respectively (P \ 0.001). After adjustment for other patient characteristics, BRCA1 carriers had a significantly better OS (HR:0.29;95% CI:0.13-0.62, P = 0.02) compared with patients with sporadic breast cancer. More recently, consistent with our findings, Lee et al. [39] reported similar survival rates in BRCA1 mutation carriers with TN disease compared to non-carriers when treated with alkylating chemotherapy. These results suggest that deleterious BRCA1/2 mutations in TNBC do not carry an adverse prognostic significance.
Unlike HER2-positive breast cancer, currently there is no targeted biologic therapy available for TNBC, and endocrine therapy is not indicated. Thus, chemotherapy is currently the mainstay of systemic treatment. Although TNBC is biologically aggressive, chemotherapy improves the outcome to a greater extent when used in patients with TNBC than when used in patients with ER-positive subtypes [40] . Neoadjuvant studies have suggested that outcome is excellent in the minority of women with TNBC who achieve a complete pathological response (pCR); in contrast, the outcome for the majority who still have residual disease after treatment is relatively poor, reflecting the heterogeneity of triple-negative tumors [26] . Importantly, pCR rates in BRCA mutation-associated TNBC and non-BRCA mutation-associated TNBC were found to be similar [26, 41, 42] , confirming molecular and pathological similarities between the triple-negative and BRCA mutant breast cancers. While studies reported superiority of anthracycline-taxane-containing regimens in TNBC [43, 44] , there is no preferred standard form of chemotherapy for BRCA mutation-associated TNBC. Breast cancer cell lines with BRCA1/2 deficiency show profound hypersensitivity to apoptosis when treated with potent inhibitors of the enzyme poly (ADP-ribose) polymerase (PARP) [45] [46] [47] , mitoxantrone, etoposide, cisplatin, and doxorubicin [48] [49] [50] [51] . In our study, the fact that the outcomes were similar between BRCA carriers and non-carriers, most of whom received anthracycline-taxane-containing chemotherapy regimens, suggests that triple-negative BRCA mutant cancers are just as sensitive to conventional chemotherapy regimens as other high-grade TNBCs. BPO is an effective means of reducing the risk of breast and ovarian cancer in carriers of both BRCA1 and BRCA2 mutations, especially if performed before age 40 [52] [53] [54] [55] . Interestingly, the largest published cohort study showed that BPO was associated with a greater reduction in breast cancer risk for BRCA1 carriers (OR = 0.44; 95% CI:0.29-0.66; P = 0.00006) than for BRCA2 carriers (OR = 0.57; 95% CI:0.28-1.15; P = 0.11) [52] . A recent study provides evidence that BSO reduces not only cancer incidence but also all-cause mortality (HR = 0.38; 95% CI:0.24-0.62), breast cancer-specific mortality (HR = 0.38; 95% CI:0.20-0.72) and ovarian cancer-specific mortality (HR = 0.22;95% CI:0.06-0.83) [55] . The potentially larger risk reduction associated with BPO is of interest given the high proportion of ER-negative breast tumors in BRCA1 mutation carriers compared with BRCA2 mutation carriers. It is possible that estrogen deprivation after BPO confers a biologic effect as demonstrated by Zhang et al. [56] that estrogen signaling through the EGFR/Src/ERK pathway is involved in the development of ER-negative breast cancers. Larger data sets with longer follow-up are needed to define more precisely the reduction in mortality conferred by BPO.
Certain limitations of this study should be acknowledged. First, the relatively higher prevalence estimates in the current study can be explained by the highly select nature of our subject population, limiting generalizability of the findings to all patients. Second, examination of both BRCA1 and BRCA2 mutation groups together may have affected the survival outcomes as emerging data suggest that BRCA1 mutation carriers may experience differential benefits from interventions such as CPM or BPO compared with BRCA2 mutation carriers [55, 57, 58] .
In conclusion, we found a high incidence of BRCA1/2 deleterious mutations among a highly selected population of high-risk women with TNBC, confirming that referral for BRCA genetic testing should be considered for women with TNBC. We also show that overall prognoses of patients with TNBC are similar between BRCA mutation carriers and non-carriers. Moreover, the present data support the common recommendation that women with TNBC and BRCA1/2 mutations should consider BPO once they have completed childbearing. 
